Janux’s prostate cancer immunotherapy’s response rate drops, according to new early-stage data

Janux Therapeutics’ lead T cell engager has shown response rates of 30% in a new data cut from an early-stage study in prostate cancer. The product, named JANX007, is in a Phase 1 trial called ...